Repaglinide or Prandin is indicated for use in type 2 diabetes.
Repaglinide or Prandin stimulates the pancreas to secrete insulin. This action is similar to sulfonylurea's, but Repaglinide or Prandin represents a structurally different group - the meglitinides.
In type 2 diabetes, the pancreas does still function to produce some insulin - just not enough. In type 1 diabetes, the pancreas does not produce any insulin, thus Repaglinide or Prandin is not indicated for type 1 diabetes.
As with all diabetic drugs, hypoglycemia is a potential side effect - too low a blood sugar.
People with type 1 diabetes cannot use Repaglinide or Prandin. Their pancreases do not produce insulin, thus Repaglinide or Prandin has no potential action.
Repaglinide or Prandin can be taken with other diabetes medication to control their blood sugar.
Diabet Med 1996Sept;13(9 Suppl6):143
The relevant product monographs must be regarded as the appropriate sources of prescribing information.